Saman Eshaqi, spokesperson for the Health Commission of the Iranian regime’s Majlis (Parliament), criticized the judiciary’s approach to handling the case of patient deaths caused by “contaminated peritoneal dialysis solutions.” He stated that the judiciary has not provided any response on the matter, and the Thamen pharmaceutical company has not even issued an apology.
Speaking to the state-run ILNA news agency, Eshaqi questioned why, despite nearly a year having passed since the incident, “the judiciary has not clearly announced the criminal responsibility of those accused in this case or the actions taken against them.”
The Majlis member emphasized that, based on “credible reports” and “expert opinions,” pharmaceutical products from Thamen, which operates under Astan Quds Razavi, led to the deaths of at least 70 people, possibly more.
Eshaqi further pointed out the irony that Thamen has filed complaints with the Mashhad judiciary against some raw material suppliers. He questioned, “But who is supposed to file a complaint against Thamen?”
According to reports, in June 2024, Thamen—a subsidiary of Astan Quds Razavi—responded to the deaths of at least 70 people from its products by telling the media, “By order of the higher authorities, we are not permitted to speak on this matter.”
In response to the lack of progress on the investigations and the victims’ families’ complaints, the state-run Ettelaat newspaper wrote on November 7, 2024: “If the death of seventy dialysis patients due to injections with contaminated syringes still does not stir anyone’s conscience, then we must both lament the accountability of pharmaceutical officials and mourn the erosion of public conscience.”
Astan Quds Razavi is one of the largest financial institutions of the Iranian regime, operating under the direct supervision of the regime’s supreme leader, Ali Khamenei.
